IP Library › Granted Patent US 12,304,942
Granted Patent B2
US 12,304,942 · App. 16/772,260 · Granted May 20, 2025

Cell comprising a chimeric antigen receptor or a transgenic T-cell receptor and comprising a chimeric TNF receptor

Inventors: Martin Pulé (London, GB); Marco Della Peruta (London, GB)
Assignee: AUTOLUS LIMITED
C07K14/70578A61K40/11A61K40/31A61K40/4204A61K40/4211A61K40/4215A61K40/4258C07K14/7051C07K16/30C07K19/00C12N5/0636C07K16/2803C07K2319/02C07K2319/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,304,942
App. No.
16/772,260
Granted
May 20, 2025
Kind
B2
Abstract

The present invention relates to a cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) a chimeric TNF receptor (TNFR) which comprises (a) a binding domain which is capable of binding a TNFR ligand; and (b) a TNFR signalling domain.

Claims (7)

1. A cell which comprises:

(i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and

(ii) a chimeric TNF receptor (TNFR) which comprises (a) a binding domain comprising the amino acid sequence of SEQ ID NO: 8 which is capable of binding a TNFR ligand of a first TNFR, wherein the first TNFR is RANK; and (b) a TNFR signalling domain of a second TNFR comprising an amino acid sequence of SEQ ID NO: 12, 13, 14, 15, 16 or 17.

2. A pharmaceutical composition which comprises a plurality of cells according to claim 1 .

3. A method for making a cell according to claim 1 , which comprises the step of introducing:

(i) a first nucleic acid sequence which encodes a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and

(ii) a second nucleic acid sequence which encodes a chimeric TNF receptor (TNFR) which comprises (a) a binding domain comprising the amino acid sequence of SEQ ID NO: 8 which is capable of binding a TNFR ligand of a first TNFR, wherein the first TNFR is RANK; and (b) a TNFR signalling domain of a second TNFR comprising an amino acid sequence of SEQ ID NO: 12, 13, 14, 15, 16 or 17.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Jul 30, 2026
From: AUTOLUS LIMITED
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 076084/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2020
From: PULÉ, MARTIN; PERUTA, MARCO DELLA
To: AUTOLUS LIMITED
Reel/Frame 052922/0448 →
Priority Claims (1)
GB 1720949 · Dec 15, 2017 · national
Continuity (1)
Related Publication 20210095003A1 · Apr 1, 2021
References Cited (28)
US 7052906B1 · Lawson et al. · 2006 [cited by applicant]
US 20060009450A1 · Tobinick · 2006 [cited by applicant]
US 20130266551A1 · Campana et al. · 2013 [cited by applicant]
US 20160096892A1 · Brogdon · 2016 [cited by examiner]
US 20220145325A1 · Puléet al. · 2022 [cited by applicant]
US 20220364116A1 · Puléet al. · 2022 [cited by applicant]
US 20230113183A1 · McKenzie et al. · 2023 [cited by applicant]
WO WO0236769A2 · 2002 [cited by applicant]
WO WO2005044996A2 · 2005 [cited by applicant]
WO WO2013033626A2 · 2013 [cited by applicant]
WO WO2013153391A1 · 2013 [cited by applicant]
WO WO2016014576A1 · 2016 [cited by applicant]
WO WO2016093878A1 · 2016 [cited by applicant]
WO WO2016174461A1 · 2016 [cited by applicant]
WO WO2017028374A1 · 2017 [cited by applicant]
WO WO2020183131A1 · 2020 [cited by applicant]
WO WO2021205176A2 · 2021 [cited by applicant]
Wang et al, 2012. Immunology. 137: 114-116. [cited by examiner]
Tokuriki et al, 2009, Current Opinion in Structural Biology. 19: 596-604. [cited by examiner]
Bhattacharya et al, 2017. Plos One. 12(3): e0171355, pp. 1-22 as printed. [cited by examiner]
Donnelly et al., “The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences,” J. Gen. Virol. 82:1027-1041 (2001). [cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/GB2018/053629 dated Feb. 19, 2019. [cited by applicant]
Wang et al., “Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers,” Clinical Cancer Research 23(9):2267-2276 (2017). [cited by applicant]
Watts, “TNF/TNFR Family Members in Costimulation of T Cell Responses,” Annu. Rev. Immunol. 23:23-68 (2005). [cited by applicant]
Long et al., “4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors,” Nature Medicine, 21(6):581-590 (2015). [cited by applicant]
Van der Stegen et al., “The Pharmacology of Second-Generation Chimeric Antigen Receptors,” Nature Reviews Drug Discovery, 15(7):499-509 (2015). [cited by applicant]
McKenzie C., et al., “Novel Fas-TNFR Chimeras that Prevent Fas Ligand-Mediated Kill and Signal Synergistically to Enhance CART Cell Efficacy”, Molecular Therapy-Nucleic Acids, vol. 32, XP093069478, Jun. 1, 2023, pp. 603… [cited by applicant]
Oda S.K., et al., “A Fas-4-IBB Fusion Protein Converts a Death to a Pro-Survival Signal and Enhances T Cell Therapy”, Journal of Experimental Medicine, XP55842282A, vol. 217, No. 12, 2020, 20 Pages. [cited by applicant]